In today's Just the Facts....
Prescient Therapeutics has secured Orphan Drug Designation in Europe for its lead therapy, PTX-100, targeting cutaneous T-cell lymphoma. The status unlocks key regulatory benefits, including ten years of market exclusivity, and builds on the drug’s existing FDA Fast Track approval.
American Rare Earths has upgraded the MRE at its Cowboy State Mine. New channel samples delivered standout rare-earth grades—one hitting a record 13,800 PPM.
New Frontier Minerals has gained access to a breakthrough rare-earth processing route, after test work on Harts Range ore delivered about a 20-fold lift in total rare-earth content in a single step. Through its partnership with Metallium, the process also sharply upgrades dysprosium and terbium — helping build much-needed Western refining capacity.
BCAL Diagnostics says its pancreatic and ovarian cancer tests remain on track for a January 2026 launch. Partner ClearNote has secured UK regulatory approval, while new clinical data expands BCAL’s breast screening market.
#Biotech #MedTech #CancerDiagnostics #RareDisease #CriticalMinerals #RareEarths #MiningNews #Exploration #Oncology #ClinicalData #WomenHealth